Drug pricing too important to be left to narrow regulatory agencies

BY JONATHAN HENDERSON, MD 

APR 23, 2021

Very shortly before leaving office, the Trump administration released the Most Favored Nation (MFN) drug pricing interim final rule that was meant to help control and reduce Medicare’s costs for certain medications used in physicians’ offices, including several life-saving prostate cancer treatments. If the rule takes effect, physicians in the United States will receive one of the lowest payments for treating patients with drugs among the 22 most economically developed countries in the world. Very shortly before leaving office, the Trump administration released the Most Favored Nation (MFN) drug pricing interim final rule that was meant to help control and reduce Medicare’s costs for certain medications used in physicians’ offices, including several life-saving prostate cancer treatments. If the rule takes effect, physicians in the United States will receive one of the lowest payments for treating patients with drugs among the 22 most economically developed countries in the world.

Read more.  


• • •